Reports Q3 revenue EUR 1.37M vs EUR 814,000 last year. “We are extremely pleased with the continued progress in advancing our Axiomer RNA editing platform and believe we’re only at the beginning of reaching the potential of this technology,” said Daniel A. de Boer, Chief Executive Officer of ProQR. “We expect that the body of data on our platform and initial pipeline programs will start to ramp up significantly in 2024. Along with our preclinical proof of concept data for the platform, a partnership with Eli Lilly, a leading IP position, and strong cash runway with more than EUR 120.6 million providing runway into mid-2026, we believe ProQR has strong fundamentals in place to execute on our strategy.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PRQR:
- ProQR Announces Third Quarter 2023 Operating and Financial Results
- ProQR Therapeutics announces strengthened IP with new U.S. patent
- ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing
- PRQR Earnings this Week: How Will it Perform?
- ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference
